Today, the FDA released a new suite of resources to educate patients about biosimilars.
Today, the FDA released a new suite of resources to educate patients about biosimilars.
The new materials, “Biosimilars Basics for Patients,” explain that biosimilars are safe and effective medications that “are FDA-approved biologic medications that are compared to another medication—the original biologic.” The FDA describes biosimilars are being made “from natural sources” and developed “using advanced science.”
The resources explain that biosimilars can be expected to have the same benefits and risks, and that they may provide more treatment options, increase competition in the marketplace, and allow for lower costs.
The FDA also provides a brief overview of the ways in which it ensures that biosimilars are safe and effective, including reviewing data, monitoring drugs post-launch, and reviewing patient safety reports.
A frequently-asked-question (FAQ) section of the guide addresses questions such as how patients can tell whether they are receiving a biosimilar (the FDA suggests asking a doctor or pharmacist), whether it is safe to switch to a biosimilar (biosimilars can generally be used whether or not a patient has been first treated with a reference, says the guide), and whether individual patients can expect to see cost savings from biosimilars (health insurance plan providers are best situated to provide this information, according to the FAQ).
The FDA’s materials also include a “Biosimilar Basics” infographic and a one-page explanation of biosimilars that highlights the fact that “prescribers and patients should have no concerns about using these medications instead of reference products.”
The resources deliver on the Biosimilar Action Plan’s commitment to develop effective communications to improve upon the understanding of biosimilars among patients and other stakeholders. In the plan, the FDA committed to developing a “one-pager” for patients and to pursue video-format communications that can be disseminated on social media for patients and other key audiences.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.